A class action lawsuit has been filed accusing GlaxoSmithKline of lying to the Patent office and dickering with fake patent litigation against generic drug makers to fraudulently stymie generic versions of Wellbutrin from hitting the market. The lawsuit applies to people who directly bought Wellbutrin from GSK in 100 or 150mg hits between Jan 24, 2002 and June 30, 2006. Obviously, the long GSK could keep a generic version of their drug off the market, the more money they could make. People interested in joining could probably contact the firm of Roda and Nast, lead plaintiff team, for more information.
Antitrust Class Action Certified Against GlaxoSmithKline [Law.com]